UOC
SGMO

UBS O'Connor’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

UBS O'Connor’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-50,000
Closed -$784K – 878
2015
Q1 		$784K Sell
50,000
-30,000
-38% -$464K 0.02% 438
2014
Q4 		$1.22M Sell
80,000
-40,000
-33% -$486K 0.02% 336
2014
Q3 		$1.29M Buy
120,000
+20,000
+20% +$261K 0.02% 315
2014
Q2 		$1.53M Sell
100,000
-130,000
-57% -$1.87M 0.01% 298
2014
Q1 		$4.16M Buy
230,000
+166,041
+260% +$3.2M 0.08% 252
2013
Q4 		$888K Sell
63,959
-161,041
-72% -$1.85M 0.02% 309
2013
Q3 		$2.36M Buy
+225,000
New +$2.23M 0.05% 264

Other funds holding SGMO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

UBS O'Connor's SGMO Position: Q2 2015 in Review

UBS O'Connor sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2015, closing a stake of 50,000 shares — an estimated $784K sold.

UBS O'Connor first reported a position in SGMO in Q3 2013 and held it in 7 quarters. The position peaked at $4.16M in Q1 2014. 156 funds tracked by Wall St. Rank hold SGMO as of Q2 2015.

  • UBS O'Connor reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2015 after selling out during the quarter.
  • UBS O'Connor sold 50,000 SANGAMO THERAPEUTICS INC shares in Q2 2015, an estimated $784K.
  • UBS O'Connor first reported a position in SANGAMO THERAPEUTICS INC in Q3 2013 and held it in 7 quarters.
  • UBS O'Connor's SANGAMO THERAPEUTICS INC position peaked at $4.16M in Q1 2014.
  • 156 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2015.

Based on UBS O'Connor's 13F filing for Q2 2015, filed 13 Aug 2015.